BioLASCO Taiwan Co., Ltd.
BioLASCO Taiwan Co., Ltd. operates an animal breeding center to produce specific pathogen-free laboratory mice and rats in Taiwan and internationally. It offers lab animals, such as rat, mice, and others, as well as surgical services; rodents housing, washing solutions, workstations, animal housing and management solutions, lab animal research equipment, clean solution, preclinical imaging system… Read more
BioLASCO Taiwan Co., Ltd. (6662) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, BioLASCO Taiwan Co., Ltd. (6662) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BioLASCO Taiwan Co., Ltd. - Net Assets Trend (None–None)
This chart illustrates how BioLASCO Taiwan Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioLASCO Taiwan Co., Ltd. (None–None)
The table below shows the annual net assets of BioLASCO Taiwan Co., Ltd. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BioLASCO Taiwan Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BioLASCO Taiwan Co., Ltd. Competitors by Market Cap
The table below lists competitors of BioLASCO Taiwan Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fine Besteel Co. Ltd.
KQ:133820
|
$8.95K |
|
Cognetivity Neurosciences Ltd
PINK:CGNSF
|
$8.96K |
|
We Can Medicines Co., Ltd.
TWO:6929
|
$8.96K |
|
Future Generation Global Ltd
AU:FGG
|
$8.98K |
|
MATD3F
SA:MATD3F
|
$8.95K |
|
Watkin Jones PLC
LSE:WJG
|
$8.93K |
|
Journeo PLC
LSE:JNEO
|
$8.92K |
|
Ha Noi Education Development And Investment JSC
VN:EID
|
$8.92K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLASCO Taiwan Co., Ltd.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BioLASCO Taiwan Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLASCO Taiwan Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BioLASCO Taiwan Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLASCO Taiwan Co., Ltd. (6662) | NT$- | N/A | N/A | $8.95K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |